Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup or three of stimulation. Remember that no prescription is required, which means you need not worry about rebates. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch. …

The Centers for Medicare and Medicaid Services will slightly increase coverage for CAR-T therapies administered at certain large hospitals, and is considering other ways to pay more for the treatments, Reuters writes. CMS issued a proposed rule raising its maximum payment from 50% of estimated costs to 65%, which would increase reimbursement to $242,450 from the current $186,500. But that is still far short of actual costs. Gilead Sciences (GILD) and Novartis (NVS) charge $373,000 for advanced lymphoma, and Kymriah costs $475,000 for a type of pediatric leukemia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!